Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History & Milestones
  • Products
    • Product Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
MENU Close

2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6

2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6

  • Post author:alarpharm
  • Post published:13 . 5 . 2022
  • Post category:Media releases

You Might Also Like

2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367.

3 . 5 . 2021

2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139..

17 . 12 . 2021

2022/12/05 ALA-1000 received notice of patent allowance from Companies and Intellectual Property Commission of Republic of South Africa , Application No. 2020/04582

6 . 12 . 2022

2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B

26 . 7 . 2023

2023/08/07 ALA-3000 has received an Resolution of acceptance to registration from Instituto Nacional de Propiedad Industrial (INAPI)-Chile after the examination. (Patent Application No. 202101803)

10 . 8 . 2023
  • News
  • Events
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History & Milestones
  • Company Profile
  • Leadership Team
  • History & Milestones

PRODUCTS

  • Product Pipeline
  • Contract Manufacturing
  • Product Pipeline
  • Contract Manufacturing

MEDIA

  • News
  • Events
  • News
  • Events

INVESTORS

  • Stock Info
  • Financials
  • Stock Info
  • Financials

CONTACT US

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Events
  • Investors
    • Stock Info
    • Financials
  • Contact Us
    • Contact Us
×

Cart